202P - Influence of adjuvant chemotherapy on anti-müllerian hormone (AMH) level in patients younger than 35 years treated for an early breast cancer (EBC)

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Breast Cancer
Presenter Mathilde Saint-Ghislain
Citation Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364
Authors M. Saint-Ghislain1, F. Clatot2, M. Degrémont3, M. Leheurteur2, M. David3, C. Veyret2, F. Di Fiore2, A. Perdrix3
  • 1Medical Oncology, Centre Henri Becquerel, 76000 - Rouen/FR
  • 2Medical Oncology, Centre Henri Becquerel, Rouen/FR
  • 3Biopathology, Centre Henri Becquerel, 76000 - Rouen/FR

Abstract

Background

The overall negative influence of chemotherapy on ovarian reserve is well established. Since few years, AMH is used as a fertility marker, both in assisted reproductive technology and oncology. Surprisingly, if young patients are the most ones concerned with fertility questions, the specific impact of adjuvant chemotherapy for EBC in this population is unknown. In this context, we analysed AMH in patients ≤ 35 years presenting an EBC, before any treatment, at 1, 3 and 5 years after diagnosis.

Methods

This is a monocentric retrospective study. Patients aged ≤35 years treated for EBC between 2008 and 2014, with frozen heparined plasma samples before and after chemotherapy exposure and with a written consent for research use were included. All analysis were performed simultaneously with Elecsys® AMH assay (Roche Diagnostics). Statistics were performed using Mann-Whitney or Wilcoxon tests.

Results

Fifty-four patients were included, 23 (43%) had a triple negative and 29 (54%) a hormonal positive receptors tumor. Median age at diagnosis was 31.5 years (range 22-35). Median AMH before treatment was 2.12 ng/mL (range 0.33-17.5) and dropped to 0.13 ng/mL (0.01-6.1, p 

Conclusions

Despite a normal ovarian reserve before treatment, AMH decreases deeply 1 year after diagnosis, whatever the age of the patient. A slight recovery can be observed 3 years after diagnosis, without ranging the normal expected values for the age. Use of taxanes seems to increase gonadotoxicity.

Clinical trial identification

Legal entity responsible for the study

Centre Henri Becquerel

Funding

Centre Henri Becquerel, Department of Biopathology

Disclosure

All authors have declared no conflicts of interest.